Endotherapia

Authors: Geffard, Michel; de Bisschop, Laetitia; Duleu, Sebastien; Pouns, Olivier; Ferran, Guillaume; Bessede, Alban; Hassaine, Nadine; Autran, Jean-Louis; Bodet, Dominique; Mangas, Arturo; Covenas, Rafael

Source: Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Volume 9, Number 3, September 2010 , pp. 197-211(15)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

OR

Price: $71.00 plus tax (Refund Policy)

Abstract:

Endotherapia is a new therapeutic approach against chronic diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and rheumatoid arthritis. It combines the evaluation of circulating antibodies directed against specific self-antigens and self-antigens modified by free radicals. Here, we review the literature concerning this topic. In addition, our biological assays have allowed us to follow up the evolution of chronic diseases along time, checking remission phases. For more than 25 years, our scientific group has suggested that the chronicity of diseases may be due to nonpathological bacteria living in different biotopes.

Endotherapia is the result of immunopathologic work addressing chronic incurable diseases with a multifactorial etiology. Several genes are susceptible to toxic environmental immunologic agents. Thus, the intestinal ecosystem plays an important role in these mechanisms.

Therapy is a “tailor-made” combination (MG1/RA, GEMSP) of the small molecules (e.g., vitamins…) linked to poly-L-lysine (PLL). Each individual linkage to PLL offers great advantages owing to the chemical characteristics of PLL (e.g., non-immunogenic), increasing the half-life of the active PLL derivatives. Clinical trials have enabled us to confirm very good safety. Our results confirm the efficacy of the approach and we believe that it could be very promising for chronic diseases.

Keywords: Amyotrophic Lateral Sclerosis; Endotherapia; GEMSP; MG1/RA; Multiple Sclerosis; Poly-L-Lysine; Rheumatoid Arthritis; clinical trials

Document Type: Research Article

Publication date: September 1, 2010

More about this publication?
  • Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of new Anti-Inflammatory & Anti-Allergy Agents.

    Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in Anti-Inflammatory & Anti-Allergy Medicinal Chemistry.

    Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in Anti-Inflammatory & Anti-Allergy Agents drug discovery.

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page